Prophylactic surgery in women with a hereditary to breast and ovarian cancer

Journal of Clinical Oncology

Volumn 18, Issue 9, 2000, Pages 1980-1995

  Eisen, Andrea ^a   Rebbeck, Timothy R ^a   Wood, William C ^a   Weber, Barbara L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SURGERY; FEMALE; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0034017713     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.9.1980     Document Type: Review

References (146)

1. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371-1388, 1998
2. Powles T, Eeles R, Ashley S, et al: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98-101, 1998
3. Veronesi U, Maisonneuve P, Costa A, et al: Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women - Italian Tamoxifen Prevention Study. Lancet 352:93-97, 1998
4. Narod SA, Risch H, Moslehi R, et al: Oral contraceptives and the risk of hereditary ovarian cancer: Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339:424-428, 1998
5. Burke W, Daly M, Garber J, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2-Cancer Genetics Studies Consortium. JAMA 277:997-1003, 1997
6. Lynch HT, Krush AJ: Carcinoma of the breast and ovary in three families. Surg Gynecol Obstet 133:644-648, 1971
7. Wooster R, Bignell G, Lancaster J, et al: Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792, 1995 (published erratum appears in Nature 379:749, 1996)
8. Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71, 1994
9. Ford D, Easton DF, Peto J: Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457-1462, 1995
10. Oddoux C, Struewing JP, Clayton CM, et al: The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14:188-190, 1996
11. Roa BB, Boyd AA, Volcik K, et al: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14:185-187, 1996
12. Struewing JP, Hange P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408, 1997
13. Struewing JP, Abeliovich D, Peretz T, et al: The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11:198-200, 1995 (published erratum appears in Nat Genet 1996 12:110, 1996)
14. Offit K: Clinical Cancer Genetics: Risk Counseling and Management. New York, NY, Wiley-Liss, Inc. 1998
15. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689, 1998
16. Ford D, Easton DF, Bishop DT, et al: Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343:692-695, 1994
17. Hasten DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Am J Hum Genet 56:263-271, 1995
18. Garcia-Patino E, Gomendio B, Lleonart M, et al: Loss of heterozygosity in the region including the BRCA1 gene on 17q in colon cancer. Cancer Genet Cytogenet 104:119-123, 1998
19. Thorlacius S, Olafsdottir G, Tryggvadottir L, et al: A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypcs. Nat Genet 13:117 119, 1996
20. Stefanek ME, Helzlsouer KJ, Wilcox PM, et al: Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med 24:412-419, 1995
21. Eisinger F, Julian-Reynier C, Stoppa-Lyonnet D, et al: Breast and ovarian cancer prone women and prophylactic surgery temptation. J Clin Oncol 16:2573-2575, 1998 (letter)
22. Lynch HT, Lemon SJ, Durham C, et al: A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer 79:2219-2228, 1997
23. Hallowell N: You don't want to lose your ovaries because you think "I might become a man": Women's perceptions of prophylactic surgery as a cancer risk management option. Psychooncology 7:263-275, 1998
24. Vasen HFA, Haites NE, Evans DGR, et al: Current policies for surveillance and management in women at risk of breast and ovarian cancer: A survey among 16 European family cancer clinics. Eur J Cancer 34:1922-1926, 1998
25. Houn F, Helzlsouer KJ, Friedman NB, et al: The practice of prophylactic mastectomy: A survey of Maryland surgeons. Am J Public Health 85:801-805, 1995
26. Nguyen HN, Averette HE, Janicek M: Ovarian carcinoma: A review of the significance of familial risk factors and the role of prophylactic oophorectomy in cancer prevention. Cancer 74:545-555, 1994
27. Studd J: Prophylactic oophorectomy. Br J Obstet Gynaecol 96:506-509, 1989
28. Meijer WJ, van Lindert AC: Prophylactic oophorectomy. Eur J Obstet Gynecol Reprod Biol 47:59-65, 1992
29. Jacobs I, Oram D: Prevention of ovarian cancer: A survey of the practice of prophylactic oophorectomy by fellows and members of the Royal College of Obstetricians and Gynaecologists. Br J Obstet Gynaecol 96:510-515, 1989
30. Geary M, Geoghegan A, Foley M: Prevention of ovarian cancer: A survey of the practice of prophylactic oophorectomy by consultant gynaecologists in Ireland. Ir Med J 90:186-187, 1997
31. Conklin BH, McGuire PA, Weiler PL, et al: A survey of the practice of prophylactic oophorectomy by gynecologists in the state of Alaska. Alaska Med 38:71-74, 1996
32. Mezzopane R, Ricci E, Chatenoud L, et al: Attitudes and clinical practice of Italian gynecologists towards prophylactic oophorectomy during hysterectomy for benign conditions. Maturitas 24:157-159, 1996
33. Averette HE, Hoskins W, Nguyen HN, et al: National survey of ovarian carcinoma: I. A patient care evaluation study of the American College of Surgeons. Cancer 71:1629-1638, 1993
34. Sightler SE, Boike GM, Estape RE, et al: Ovarian cancer in women with prior hysterectomy: A 14-year experience at the University of Miami. Obstet Gynecol 78:681-684, 1991
35. Rozario D, Brown I, Fung MF, et al: Is incidental prophylactic oophorectomy an acceptable means to reduce the incidence of ovarian cancer? Am J Surg 173:495-498, 1997
36. Kontoravdis A, Kalogirou D, Antoniou G, et al: Prophylactic oophorectomy in ovarian cancer prevention. Int J Gynaecol Obstet 54:257-262, 1996
37. Schwartz PE: The role of prophylactic oophorectomy in the avoidance of ovarian cancer. Int J Gynaecol Obstet 39:175-184, 1992
38. Grann VR, Panageas KS, Whang W, et al: Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 16:979-985, 1998
39. Lynch HT, Severin MJ, Mooney MJ, et al: Insurance adjudication favoring prophylactic surgery in hereditary breast-ovarian cancer syndrome. Gynecol Oncol 57:23-26, 1995
40. Glazier AK: Genetic predispositions, prophylactic treatments and private health insurance: Nothing is better than a good pair of genes. Am J Law Med 23:45-68, 1997
41. Wapnir IL, Rabinowitz B, Greco RS: A reappraisal of prophylactic mastectomy. Surg Gynecol Obstet 171:171-184, 1990
42. Petersson C, Pandis N, Mertens F, et al: Chromosome aberrations in prophylactic mastectomies from women belonging to breast cancer families. Genes Chromosom Cancer 16:185-188, 1996
43. Teixeira MR, Pandis N, Gerdes AM, et al: Cytogenetic abnormalities in an in situ ductal carcinoma and five prophylactically removed breasts from members of a family with hereditary breast cancer. Breast Cancer Res Treat 38:177-182, 1996
44. Bieche I, Lidereau R: Genetic alterations in breast cancer. Genes Chromosom Cancer 14:227-251, 1995
45. Fisher J, Maxwell GP, Woods J: Surgical alternatives in subcutaneous mastectomy reconstruction. Clin Plast Surg 15:667-676, 1988
46. Horton CE, Dascombe WH: Total mastectomy: Indications and techniques. Clin Plast Surg 15:677-687, 1988
47. Freeman BS, Wiemer DR: Total glandular mastectomy: Modifications of the subcutaneous mastectomy for use in premalignant disease of the breast. Plast Reconstr Surg 62:167-172, 1978
48. Carlson GW, Bostwick J III, Styblo TM, et al: Skin-sparing mastectomy: Oncologic and reconstructive considerations. Ann Surg 225:570-575; discussion 575-578, 1997
49. Rubin LR: Prophylactic mastectomy with immediate reconstruction for the high-risk woman. Clin Plast Surg 11:369-381, 1984
50. Hicken N: Mastectomy: A clinical pathologic study demonstrating why most mastectomies result in incomplete removal of the mammary gland. Arch Surg 40:6-14, 1940
51. Goldman LD, Goldwyn RM: Some anatomical considerations of subcutaneous mastectomy. Plast Reconstr Surg 51:501-505, 1973
52. Temple WJ, Lindsay RL, Magi E, et al. Technical considerations for prophylactic mastectomy in patients at high risk for breast cancer. Am J Surg 161:413-415, 1991
53. Klamer TW, Donegan WL, Max MH: Breast tumor incidence in rats after partial mammary resection. Arch Surg 118:933-935, 1983
54. Wong JH, Jackson CF, Swanson JS, et al. Analysis of the risk reduction of prophylactic partial mastectomy in Sprague-Dawley rats with 7.12-dimethylbenzanthracene-induced breast cancer. Surgery 99: 67-71, 1986
55. Nelson H, Miller SH, Buck D, et al: Effectiveness of prophylactic mastectomy in the prevention of breast tumors in C3H mice. Plast Reconstr Surg 83:662-669, 1989
56. Baasch M, Nielsen SF, Engholm G, et al: Breast cancer incidence subsequent to surgical reduction of the female breast. Br J Cancer 73:961-963, 1996
57. Osteen RT: Reconstruction after mastectomy. Cancer 76:2070-2074, 1995
58. Noone RB, Frazier TG, Noone GC, et al: Recurrence of breast carcinoma following immediate reconstruction: A 13-year review. Plast Reconstr Surg 93:96-106; discussion 107-108, 1994
59. Eberlein TJ, Crespo LD, Smith BL, et al: Prospective evaluation of immediate reconstruction after mastectomy. Ann Surg 218:29-36, 1993
60. Schneiderman MA, Axtell LM: Deaths among female patients with carcinoma of the breast treated by a surgical procedure only. Surg Gynecol Obstet 148:193-195, 1979
61. Holzgreve W, Beller FK: Surgical complications and follow-up evaluation of 163 patients with subcutaneous mastectomy. Aesthetic Plast Surg 11:45-48, 1987
62. Budd DC, Cochran RC, Sturtz DL, et al: Surgical morbidity alter mastectomy operations. Am J Surg 135:218-220, 1978
63. Chen J, Gutkin Z, Bawnik J: Postoperative infections in breast surgery. J Hosp Infect 17:61-65, 1991
64. Vinton AL, Traverso LW, Jolly PC: Wound complications after modified radical mastectomy compared with tylectomy with axillary lymph node dissection. Am J Surg 161:584-588, 1991
65. Wedgwood KR, Benson EA: Non-tumour morbidity and mortality after modified radical mastectomy. Ann R Coll Surg Engl 74:314-317, 1992
66. Tadych K, Donegan WL: Postmastectomy seromas and wound drainage. Surg Gynecol Obstet 165:483-487, 1987
67. O'Brien W, Hasselgren PO, Hummel RP, et al: Comparison of postoperative wound complications and early cancer recurrence between patients undergoing mastectomy with or without immediate breast reconstruction. Am J Surg 166:1-5, 1993
68. Stevens PE, Dibble SL, Miaskowski C: Prevalence, characteristics, and impact of postmastectomy pain syndrome: An investigation of women's experiences. Pain 61:61-68, 1995
69. Kwekkeboom K: Postmastectomy pain syndromes. Cancer Nurs 19:37-43, 1996
70. Gabriel SE, Woods JE, O'Fallon WM, et al: Complications leading to surgery after breast implantation. N Engl J Med 336:677-682, 1997
71. Schrag D, Kuntz KM, Garber JE, et al: Decision analysis: Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336:1465-1471, 1997 (published erratum appears in N Engl J Med 337:434, 1997)
72. Eldar S, Meguid MM, Beatty JD: Cancer of the breast after prophylactic subcutaneous mastectomy. Am J Surg 148:692-693, 1984
73. Goodnight JE Jr, Quagliana JM, Morton DL: Failure of subcutaneous mastectomy to prevent the development of breast cancer. J Surg Oncol 26:198-201, 1984
74. Ziegler LD, Kroll SS: Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 14:451-454, 1991
75. Bowers DG Jr, Radlauer CB: Breast cancer after prophylactic subcutaneous mastectomies and reconstruction with silastic prostheses. Plast Reconstr Surg 44:541-544, 1969
76. Holleb AI, Montgomery R, Farrow JH: "The hazard of incomplete simple mastectomy. Surg Gynecol Obstet 121:819-822, 1965
77. Robbins GF, Berg SW: Bilateral primary breast cancers. Cancer 17:1501-1527, 1964
78. Mumounas EP, Bryant J, Fisher B, et al: Primary breast cancer (PBC) as a risk factor for subsequent contralateral breast cancer (CBC): NSABP experience from nine randomized adjuvant trials. Breast Cancer Res Treat 50:230, 1998 (abstr)
79. Frank TS, Manley SA, Olopade OI, et al: Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16:2417-2425, 1998
80. Page DL, Dupont WD: Indicators of increased breast cancer risk in humans. J Cell Biochem Suppl 160:175-182, 1992
81. Staren ED, Robinson DA, Witt TR, et al: Synchronous, bilateral mastectomy. J Surg Oncol 59:75-79, 1995
82. Lee JS, Grant CS, Donohue JH, et al: Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Surgery 118:640-647; discussion 647-648, 1995
83. Gershenwald JE, Hunt KK, Kroll SS, et al: Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer. Ann Surg Oncol 5:529-538, 1998
84. Hoffman E: The contralateral breast in ipsilateral breast carcinoma. South Med J 83:1009-1015, 1990
85. Beller FK, Nienhaus H, Niedner W, et al: Bilateral breast cancer: The frequency of undiagnosed cancers. Am J Obstet Gynecol 155:247-255, 1986
86. Ringberg A, Palmer B, Linell F: The contralateral breast at reconstructive surgery after breast cancer operation: A histopathological study. Breast Cancer Res Treat 2:151-161, 1982
87. Leis HP Jr: Selective, elective, prophylactic contralateral mastectomy. Cancer 28:956-961, 1971
88. Hartmann LC, Schaid DJ, Woods JE, et al: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77-84, 1999
89. Pennisi VR, Capozzi A: Subcutaneous mastectomy data: A final statistical analysis of 1500 patients. Aesthetic Plast Surg 13:15-21, 1989
90. Johannsson OT, Ranstam J, Borg A, et al: Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden. J Clin Oncol 16:397-404, 1998
91. Couch FJ, DeShano ML, Blackwood MA, et al: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336:1409-1415, 1997
92. Phelan CM, Lancaster JM, Tonin P, et al: Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 13:120-122, 1996 (published erratum appears in Nat Genet ;13:374, 1996)
93. Thorlacius S, Sigurdsson S, Bjarnadottir H, et al: Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 60:1079-1084, 1997
94. Weeks JC, Tiemey MR, Weinstein MC: Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 325:81-86, 1991
95. Smith TJ, Hillner BE: The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol 11:771-776, 1993
96. Meyer L, Ringberg A: A prospective study of psychiatric and psychosocial sequelae of bilateral subcutaneous mastectomy. Scand J Plastic Reconstr Surg 20:101-107, 1986
97. Goin MK, Goin JM: Psychological reactions to prophylactic mastectomy synchronous with contralateral breast reconstruction. Plast Reconstr Surg 70:355-359, 1982
98. Anonymous: Ovarian ablation in early breast cancer: Overview of the randomised trials - Early Breast Cancer Trialists' Collaborative Group. Lancet 348:1189-1196, 1996
99. Young-Fadok TM, Wolff BG, Nivatvongs S, et al: Prophylactic oophorectomy in colorectal carcinoma: Preliminary results of a randomized, prospective trial. Dis Colon Rectum 41:277-283; discussion 283-285, 1998
100. Salazar H, Godwin AK, Daly MB, et al: Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 88:1810-1820, 1996
101. Gusberg SB, Deligdisch L: Ovarian dysplasia: A study of identical twins. Cancer 54:1-4, 1984
102. Resta L, Russo S, Colucci GA, et al: Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol 82:181-186, 1993
103. Stratton JF, Buckley CH, Lowe D, et al: Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation: United Kingdom Coordinating Committee on Cancer Res (UKCCCR) Familial Ovarian Cancer Study Group. J Natl Cancer Inst 91:626-628, 1999
104. Russell JB: Laparoscopic oophorectomy. Curr Opin Obstet Gynecol 7:295-298, 1995
105. Menczer J, Dan U, Oelsner G: Laparoscopic prophylactic oophorectomy in women belonging to ovarian cancer-prone families: Advantages and shortcomings. Eur J Gynaecol Oncol 15:105-107, 1994
106. Daly M, Obrams GI: Epidemiology and risk assessment for ovarian cancer. Semin Oncol 25:255-264, 1998
107. Kovac SR, Cruikshank SH: Guidelines to determine the route of oophorectomy with hysterectomy. Am J Obstet Gynecol 175:1483-1488, 1996
108. Sheth SS: The place of oophorectomy at vaginal hysterectomy. Br J Obstet Gynaecol 98:662-666, 1991
109. Menczer J, Ben-Baruch G: Familial ovarian cancer in Israeli Jewish women. Obstet Gynecol 77:276-277, 1991
110. Escobedo LG, Peterson HB, Grubb GS, et al: Case-fatality rates for tubal sterilization in U.S. hospitals, 1979 to 1980. Am J Obstet Gynecol 160:147-150, 1989
111. Weber AM, Lee JC: Use of alternative techniques of hysterectomy in Ohio, 1988-1994. N Engl J Med 335:483-489, 1996 (published erratum appears in N Engl J Med 335:1406, 1996)
112. Goodno JA Jr, Powers TW, Harris VD: Ureteral injury in gynecologic surgery: A ten-year review in a community hospital. Am J Obstet Gynecol 172:1817-1820; discussion 1820-1822, 1995
113. Querleu D, Chapron C, Chevallier L, et al: Complications of gynecologic laparoscopic surgery: A French multicenter collaborative study. N Engl J Med 328:1355, 1993 (letter)
114. Bateman BG, Kolp LA, Hoeger K: Complications of laparoscopy: Operative and diagnostic. Fertil Steril 66:30-35, 1996
115. Mirhashemi R, Harlow BL, Ginsburg ES, et al: Predicting risk of complications with gynecologic laparoscopic surgery. Obstet Gynecol 92:327-331, 1998
116. Brinton LA, Schairer C, Hoover RN, et al: Menstrual factors and risk of breast cancer. Cancer Invest 6:245-254, 1988
117. Struewing JP, Watson P, Easton DF, et al: Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 33-35, 1995
118. Rebbeck TR, Levin AM, Eisen A, et al: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91:1475-1479, 1999
119. White CD: Papillary intraperitoneal neoplasia resembling ovarian carcinoma after removal of benign ovaries. W V Med J 89:282-283, 1993
120. Kemp GM, Hsiu JG, Andrews MC: Papillary peritoneal carcinomatosis after prophylactic oophorectomy, Gynecol Oncol 47:395-397, 1992
121. Chen KT, Schooley JL, Flam MS: Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. Obstet Gynecol 66:93S-94S, 1985
122. Piver MS, Jishi MF, Tsukada Y, et al: Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: A report of the Gilda Radner Familial Ovarian Cancer Registry, Cancer 71:2751-2755, 1993
123. Tobacman JK, Greene MH, Tucker MA, et al: Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancerprone families. Lancet 2:795-797, 1982
124. Swerdlow M: Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary. Am J Obstet Gynecol 77:197-200, 1959
125. Fromm GL, Gershenson DM, Sliva EG: Papillary serous carcinoma of the peritoneum. Obstet Gynecol 75:89-95, 1990
126. Zhou J, Iwasa Y, Konishi I, et al: Papillary serous carcinoma of the peritoneum in women: A clinicopathologic and immunohistochemical study. Cancer 76:429-436, 1995
127. Schorge JO, Muto MG, Welch WR, et al: Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 90:841-845, 1998
128. Ries LAG, Kosary CL, Hankey BF, et al: SEER Cancer Statistics Review, 1973-1995. Bethesda, MD, National Cancer Institute, 1998
129. Levy-Lahad E, Catane R, Eisenberg S, et al: Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: Frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 60:1059-1067, 1997
130. Rubin SC, Benjamin I, Behbakht K, et al: Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335:1413-1416, 1996
131. Kerlikowske K, Brown JS, Grady DG: Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 80:700-707, 1992
132. NIH Consensus Development Panel on Ovarian Cancer: Ovarian cancer: Screening, treatment and follow-up. JAMA 273:491-497, 1995
133. Kritz-Silverstein D, Barrett-Connor E, Wingard DL: Hysterectomy, oophorectomy, and heart disease risk factors in older women. Am J Public Health 87:676-680, 1997
134. Colditz GA, Willett WC, Stampfer MJ, et al: Menopause and the risk of coronary heart disease in women. N Engl J Med 316:1105-1110, 1987
135. Aitken JM, Hart DM, Anderson JB, et al: Osteoporosis after oophorectomy for non-malignant disease in premenopausal women. BMJ 2:325-328, 1973
136. Belchetz PE: Hormonal treatment of postmenopausal women. N Engl J Med 330:1062-1071, 1994
137. Brinton LA: Hormone replacement therapy and risk for breast cancer. Endocrinol Metab Clin North Am 26:361-378, 1997
138. Roy JA, Sawka CA, Pritchard KI: Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits? J Clin Oncol 14:997-1006, 1996
139. Greenblatt RB, Colle ML, Mahesh VB: Ovarian and adrenal steroid production in the postmenopausal woman. Obstet Gynecol 47:383-387, 1976
140. Vermeulen A: The hormonal activity of the postmenopausal ovary. J Clin Endocrinol Metab 42:247-253, 1976
141. Judd HL, Judd GE, Lucas WE, et al: Endocrine function of the postmenopausal ovary: Concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 39:1020-1024, 1974
142. Garcia CR, Cutler WB: Preservation of the ovary: A reevaluation. Fertil Steril 42:510-514, 1984
143. Bowman M: Is screening and/or prophylactic oophorectomy for ovarian cancer of value in high risk women? Hum Reprod 12:203-204, 1997
144. Nathorst-Boos J, von Schoultz B, Carlstrom K: Elective ovarian removal and estrogen replacement therapy: Effects on sexual life, psychological well-being and androgen status. J Psychosom Obstet Gynaecol 14:283-293, 1993
145. Dennerstein L, Wood C, Burrows GD: Sexual response following hysterectomy and oophorectomy. Obstet Gynecol 49:92-96, 1977
146. Everson SA, Matthews KA, Guzick DS, et al: Effects of surgical menopause on psychological characteristics and lipid levels: The Healthy Women Study. Health Psychol 14:435-443, 1995